p16/Ki67和E6/E7 mRNA在宫颈癌筛查中的研究进展(综述)

Clinical research progress of p16 / Ki67 and E6 / E7 mRNA in screening cervical cancer

宫颈癌筛查策略在临床上的广泛应用显著降低了其发病率和病死率,但阴道镜转诊及活检给女性患者带来身体和精神负担。随着分子生物学的不断发展,学者们聚焦于生物标志物的研究与开发,简便有效的新型检测方法也被逐渐报道。该文主要总结近五年国内外宫颈癌主要筛查指标p16蛋白、Ki67抗原、E6/E7 mRNA的相关研究进展,探讨各指标间的差异与优缺点,旨在为宫颈癌筛查提供更简便有效的诊疗方法,降低阴道镜转诊率,提高检出效率。

The widespread clinical application of cervical cancer screening strategies has significantly reduced the incidence and mortality of cervical cancer,but colposcopy referrals and biopsies have brought physical and mental burdens to female patients.With the continuous development and progress of molecular biology,scholars focuse on the research of biomarkers.Simple and effective new detective methods are gradually reported.This review mainly summarizes the relevant research progress of the main screening indicators for cervical cancer,such as p16 protein,Ki67 antigen,E6/E7 mRNA in the past five years,and explores the differences and advantages and disadvantages in order to provide easier screening methods for cervical cancer to reduce clposcopy referral rate and improve detective efficiency.